
NYSTATIN TABLETS, USP (Oral)

DESCRIPTION

Nystatin is an antimycotic polyene antibiotic obtained from *Streptomyces noursei*. Its structural formula:

 $C_{47}H_{75}NO_{17}$

M.W. 926.13

Nystatin Tablets are for oral administration and contain 500,000 units of nystatin per tablet.

Nystatin Tablets contain the inactive ingredients: corn starch, confectioner sugar, hydroxypropyl cellulose, dibasic calcium phosphate, microcrystalline cellulose, talc, magnesium stearate, hypromellose, polyethylene glycol, titanium dioxide, FD&C yellow #6, FD&C red #40, FD&C blue #2 and polysorbate 80.

CLINICAL PHARMACOLOGY

Pharmacokinetics

Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.

Microbiology

Nystatin is both fungistatic and fungicidal *in vitro* against a wide variety of yeasts and yeast–like fungi.

Candida albicans demonstrates no significant resistance to nystatin *in vitro* on repeated subculture in increasing levels of nystatin; other *Candida* species become quite resistant. Generally, resistance does not develop *in vivo*. Nystatin acts by binding to sterols in the cell membrane of susceptible *Candida* species with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

INDICATIONS AND USAGE

Nystatin Tablets are intended for the treatment of non-esophageal mucus membrane gastrointestinal candidiasis.

CONTRAINDICATIONS

Nystatin Tablets are contraindicated in patients with a history of hypersensitivity to any of their components.

PRECAUTIONS

General

This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.

Pregnancy

Teratogenic Effects

Category C

Animal reproduction studies have not been conducted with nystatin. It is also not known whether nystatin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

ADVERSE REACTIONS

Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See PRECAUTIONS: General.)

Gastrointestinal

Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.

Dermatologic

Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.

Other

Tachycardia, bronchospasm, facial swelling, and nonspecific myalgia have also been rarely reported.

OVERDOSAGE

Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (see CLINICAL PHARMACOLOGY, Pharmacokinetics).

DOSAGE AND ADMINISTRATION

The usual therapeutic dosage is one to two tablets (500,000 to 1,000,000 units nystatin) three times daily. Treatment should generally be continued for at least 48 hours after clinical cure to prevent relapse.

HOW SUPPLIED

Nystatin Tablets USP, 500,000 Units are brown, film-coated tablets debossed "HP51" on one side and plain on the other side are packaged in:

bottles of 100: NDC 23155-051-01

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature].

Manufactured for:

Heritage Pharmaceuticals Inc.

Eatontown, NJ 07724 1.866.901.DRUG (3784)

Made in India.

DRUGS/PY/05131523

020002332 Revised 10/13

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Nystatin Tablets USP, 500,000 Units, 100 count bottles



NYSTATIN

Product Information				
Product Type	HUMAN PRESCRIPTION DRUG LABEL	Item Code (Source)	NDC:23155- 051	
Route of Administration	ORAL	DEA Schedule		

Active Ingredient/Active Moiety				
Ingredient Name	Basis of Strength	Strength		
NYSTATIN (NYSTATIN)	NYSTATIN	500000 [USP'U]		

Inactive Ingredients			
Ingredient Name	Strength		
STARCH, CORN			
SUCROSE			
HYDROXYPROPYL CELLULOSE			
ISOPROPYL ALCOHOL			
ANHYDRO US DIBASIC CALCIUM PHO SPHATE			
CELLULO SE, MICRO CRYSTALLINE			
TALC			
MAGNESIUM STEARATE			
HYPROMELLOSE 2910 (6 MPA.S)			
HYPROMELLOSE 2910 (3 MPA.S)			
POLYETHYLENE GLYCOL 400			
POLYETHYLENE GLYCOL 8000			
TITANIUM DIO XIDE			
FD&C YELLOW NO. 6			
FD&C RED NO. 40			
FD&C BLUE NO. 2			
POLYSORBATE 80			

Product Characteristics				
Color	BROWN	Score	no score	
Shape	ROUND	Size	10 mm	
Flavor		Imprint Code	HP;51	
Contains				

P	ackaging			
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:23155-051-01	100 in 1 BOTTLE		

	Marketing Infor	mation		
ı	Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date

ANDA	ANDA062474	10/31/2011	

Labeler - Heritage Pharmaceuticals Inc (780779901)

Establishment				
Name	Address	ID/FEI	Business Operations	
Shasun Pharmaceuticals Ltd.		915786829	MANUFACTURE(23155-051)	

Revised: 11/2013 Heritage Pharmaceuticals Inc